​

Centessa Pharmaceuticals (CNTA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Centessa Pharmaceuticals Revenue Highlights

00

Main Segment (Y)

Lixivaptan

Main Geography (Y)

Lixivaptan

Centessa Pharmaceuticals Revenue by Period

Centessa Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31--100.00%
2023-12-31$6.85M100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Centessa Pharmaceuticals generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Centessa Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-09-30-100.00%
2025-06-30--100.00%
2025-03-31$15.00M1475.21%
2024-12-31$952.25K100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$6.91M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Centessa Pharmaceuticals generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Centessa Pharmaceuticals Revenue Breakdown

Centessa Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 21
Lixivaptan$200.00M

Centessa Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 21: Lixivaptan (100.00%).

Quarterly Revenue by Product

Product/ServiceMar 25
Reportable Segment$15.00M

Centessa Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Reportable Segment (100.00%).

Centessa Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 21
Lixivaptan$200.00M

Centessa Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 21: Lixivaptan (100.00%).

Centessa Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
AAPGASCENTAGE PHARMA GROUP$980.65M$141.22K
RAREUltragenyx Pharmaceutical$560.23M$159.93M
ZLABZai Lab$398.99M$116.09M
LEGNLegend Biotech$285.14M$93.99M
XENEXenon Pharmaceuticals--
SLNOSoleno Therapeutics-$66.02M
CGONCG Oncology-$1.67M
APGEApogee Therapeutics--
CNTACentessa Pharmaceuticals--
DYNDyne Therapeutics--
CELCCelcuity-$154.00K

CNTA Revenue FAQ

What is Centessa Pharmaceuticals’s yearly revenue?

Centessa Pharmaceuticals's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $6.85M, representing an increase of 100.00% compared to 2022. CNTA's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Centessa Pharmaceuticals’s quarterly revenue?

Centessa Pharmaceuticals's quarterly revenue for Q3 2025 was $0, a 100.00% increase from the previous quarter (Q2 2025), and a 0% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $0, a -100.00% decrease from the previous quarter (Q1 2025), and a 0% increase year-over-year (Q2 2024). CNTA's quarterly revenue for Q1 2025 was $15M, a 1475.21% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is Centessa Pharmaceuticals’s revenue growth rate?

Centessa Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are Centessa Pharmaceuticals’s revenue streams?

Centessa Pharmaceuticals's revenue streams in c 21 are Lixivaptan

What is Centessa Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 21, the largest source of revenue of Centessa Pharmaceuticals was Lixivaptan. This segment made a revenue of $200M, representing 100.00% of the company's total revenue.